The Dr. Abeer AbouYabis Scholarship for Future Doctors offers a $1,000 award to undergraduate students pursuing a medical career, encouraging them to envision their impact on the future of healthcare.

The global technology spending on core administration in healthcare market is expected to grow from $34.8 billion in 2023 to $61.5 billion by 2033, at a CAGR of 5.86%. The growth is driven by advancements in technologies like edge computing, IoT, and cloud storage, as well as the need for operational efficiency and regulatory compliance.

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

EVH earnings call for the period ending March 31, 2024.

Evolent Health (EVH) delivered earnings and revenue surprises of 61.90% and 6.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (NYSE:EVH) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 3 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Evolent Health, revealing an average target of $44.0, a high estimate of $52.00, and a low estimate of $38.00. A 3.3% drop is evident in the current average compared to the previous average price target of $45.50. Investigating Analyst Ratings: An Elaborate Study The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Daniel Grosslight Citigroup Announces Buy $40.00 - Richard Close Canaccord Genuity Lowers Buy $44.00 $45.00 Anne Samuel JP Morgan Lowers Overweight $52.00 $53.00 Jeff Jones Oppenheimer Announces Outperform $45.00 - Constantine Davides JMP Securities Raises Market Outperform $38.00 $37.00 Richard Close Canaccord Genuity Lowers Buy $45.00 $47.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evolent ...Full story available on Benzinga.com

In the preceding three months, 4 analysts have released ratings for Evolent Health (NYSE:EVH), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Evolent Health, revealing an average target of $45.0, a high estimate of $52.00, and a low estimate of $38.00. A 1.47% drop is evident in the current average compared to the previous average price target of $45.67. Interpreting Analyst Ratings: A Closer Look The perception of Evolent Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Anne Samuel JP Morgan Lowers Overweight $52.00 $53.00 Jeff Jones Oppenheimer Announces Outperform $45.00 - Constantine Davides JMP Securities Raises Market Outperform $38.00 $37.00 Richard Close Canaccord Genuity Lowers Buy $45.00 $47.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Evolent Health. This information provides a snapshot of ...Full story available on Benzinga.com

The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Evolent Health, Inc. (NYSE: EVH) reported better-than-expected fourth-quarter results on Thursday. Evolent Health posted quarterly earnings of 23 cents per share, beating market estimates of 15 cents per share. The company’s quarterly sales came in at $556.05 million versus market expectations of $542.39 million, according to data from Benzinga Pro. Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year. Annual revenue increased over 45% while we continued to deliver strong earnings, driven by continued ...Full story available on Benzinga.com

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. MercadoLibre reported quarterly earnings of $3.25 per share, unchanged from the same period last year. The company reported quarterly sales of $4.26 billion, beating the analyst consensus estimate of $4.12 billion. MercadoLibre shares dipped 9.6% to $1,643.30 on Friday. Here are some other stocks moving in today's mid-day session. Gainers AXT, Inc. (NASDAQ: AXTI) shares surged 74.4% to $3.9750 after the company reported better-than-expected fourth-quarter financial results. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) shares jumped 60.8% to $8.22 after the company reported better-than-expected fourth-quarter financial results. AtlasClear Holdings, Inc. (NYSE: ATCH) rose 48% to $1.6899. EZFill Holdings Inc. (NASDAQ: EZFL) gained 44.6% to $ 1.8088. Ocean Biomedical, Inc. (NASDAQ: OCEA) jumped 42.3% to $0.7819. Gyre Therapeutics, Inc. (NASDAQ: GYRE) gained 36.2% to $21.79. Carvana Co. (NYSE: CVNA) rose 31.2% to $68.77 after the company reported fourth-quarter financial results. Sleep Number Corporation (NASDAQ: SNBR) gained 30.5% to $14.42 after the company reported better-than-expected fourth-quarter financial results. Also, Wedbush maintained a Neutral rating on the stock and raised its price target from $12 to $13.5. ATN International, Inc. (NASDAQ: ATNI) rose 26% to $ 35.72. Root, Inc. (NASDAQ: ROOT) gained 26% to $16.85 after the company reported better-than-expected fourth-quarter financial results. Following earnings, Cantor Fitzgerald upgraded the stock from Neutral to Overweight and raised its price target from $9 to $13. Infobird Co., Ltd (NASDAQ: IFBD) gained 25.7% to $3.72. Vroom, Inc. (NASDAQ: VRM) jumped 25.5% to $ 10.50. Vroom is expected to release fourth quarter earnings on March 13, 2024. ATN International, Inc. (NASDAQ: ATNI) rose 25.4% to $35.61. Intuitive Machines, Inc. (NASDAQ: LUNR) gained 22.4% to $10.14 after the company's Odysseus spacecraft landed on the Moon. Block, Inc. ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Evolent Health (NYSE:EVH) in the last three months. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 1 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.5, along with a high estimate of $45.00 and a low estimate of $37.00. A decline of 5.09% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study The standing of Evolent Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Constantine Davides JMP Securities Raises Market Outperform $38.00 $37.00 Richard Close Canaccord Genuity Lowers Buy $45.00 $47.00 Constantine Davides JMP Securities Announces Market Outperform $37.00 - Sean Dodge RBC Capital Lowers Outperform $42.00 $44.00 Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' ...Full story available on Benzinga.com